EGFR and non-small cell lung carcinoma: More recently, a retrospective study found that patients with the EGFR mutant advanced NSCLC who received the combination therapy of TKIs and chemotherapy could achieve longer PFS than those who receive TKIs alone (median, 20.5 vs. 16 months, p = 0.036), but no difference was found in OS (median, 36 vs. 29 months, p = 0.19) [15].